Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of semaglutide injection versus Wegovy in Chinese adults with obesity
CTR20244777Phase 3Completed
- Sponsor
- T-Ray Pharmaceutical
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by T-Ray Pharmaceutical. Primary endpoint: Difference between groups in percent change in body weight from baseline at end of treatment. Started Mar 2025; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20244777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244777.